Tiziani Whitmyre Inc. is a marketing agency specializing in revenue generation and brand development for B2B and life sciences companies - with specific capabilities in Life Science and Therapeutics.
18. Digital collateral:
Executive bios
Fact sheets
Luxterna timeline
2001
Proof of concept
shown in dogs published in
Nature Genetics
May 2008
Clinical data published
in the New England Journal of Medicine
April 2012
Orphan drug designation
received from the European Medicines Agency
(EMA) for Leber congenitial amaurosis (LCA)
March 2013
Spark Therapeutics
founded
March 2015
Orphan drug designation
received from the U.S. FDA for
retinitis pigmentosa (RP) 2
October 2007
First person dosed
in the U.S. in Children's Hospital of Philadelphia
(CHOP)-sponsored Phase 1 clinical trial
June 2008
Orphan drug designation
received from the U.S. Food and Drug Administration
(FDA) for Leber congenital amaurosis (LCA) 2
November 2012
Pivotal Phase 3
clinical trial initiated
November 2014
Breakthrough therapy designation
received from the U.S. FDA
July 2015
Orphan drug designation
received from the EMA for RP
The development of Spark Therapeuticsโ
investigational LUXTURNAโข
(voretigene neparvovec)
Striving to challenge the inevitability of genetic
disease by discovering, developing and delivering
treatments in ways unimaginable โ until now.
Built and supported the
site since 2016
Critical support through
aquisition by Roche
sparktx.com
19. Client since 2015
26 WordPress properties
Employee portal
5 languages
7 countries
Hosting in mainland China
Support of multiple business units
astronovaproductid.com
21. Why TW?
โข Specialize on life science clients
โข Deep experience with therapeutics firms
โข Knowledge and understanding of audiences and needs
โข Broad portfolio of in-house skills and resources
โข Proven, comprehensive solutions that generate results
23. Spark Therapeutics, Inc.
3737 Market Street
Philadelphia, PA 19104
Phone: 1-855-SPARKTX / +1 215-220-9300
ยฉ 2017 Spark Therapeutics, Inc.
sparktx.com/linkedin
communications@sparktx.com
sparktx.com
October 2016
Two-year durability data
from Phase 3 study responses presented at
the American Academy of Ophthalmology
2016 Annual Meeting
Announcement of successful completion of
the first randomized,
controlled Phase 3 trial
of a gene therapy for a genetic disease
January 2017
Amended FDA orphan drug
designation announced for โthe treatment of inherited
retinal dystrophy due to biallelic RPE65 mutationsโ
July 2016
Safety and durability data
in contralateral eye from a Phase 1 study
published in The Lancet
January 2017
Four-year efficacy
data shown from Phase 1
follow-on study
July 2017
FDA accepts
Biologics License
Application (BLA)
Webdesign
WordPressCMSintegration
Emailcommunications
SEO
Lead/tra๏ฌcgeneration
API/cloudintegrations
Marketingautomation
CRMintegration
WebServices
28. Web
Services
SEO
โข Keyword research
โข Keyword selection consulting
โข Keyword rank benchmarking
โข Content optimization
โข Content development
โข Technical assessments
โข Re-indexing management
โข Iterative implementation and reporting
29. Web
Services Tra๏ฌc generation
โข Dedicated media director
โข Established relationships with publishers
โข Custom engagements
โข Content focused
โข Placements, sponsorships, networks, remarketing
30. Web
Services
โข Custom API integrations
โข Cost-e๏ฌective 3rd-party bridges (Zapier/Piesync)
โข Job boards
โข CRM
โข Marketing automation
โข Custom analytics
โข Heat map systems
Integration
Web
Services
31. Web
Services
โข Customized, triggered communications
โข Keep track of key stakeholderโs browsing activity
โข Track businesses/organizations visiting your site
โข Track outbound communications
โข Create your own referral codes
Marketing Automation
32. Web
Services
โข Dedicated email address for maintenance requests
โข Automatic ticket generation โ typically assigned same day
โข Minor items .5 โ 1.5 turnaround
โข Custom quotes generated upon request
โข Portal view to review past requests
โข Team access
Support Portal
33. 2 Commercial St.
Sharon, MA 02067
tizinc.com
Contact JasonDodd or ChrisSullivan at 781-793-9380to discuss your next project.